2Silverberg DS,Wexler D,Blum M,et al.The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe,resistant congestive heart failure improves cardiac and renal function and functional cardiac class,and markedly reduces hospitalizations[J].J Am Coil Cardiol,2000;35(16):1737-44.
3Horwich TB,Fonarow GC,Hamilton MA,et al.Anemia is associated with worse symptoms,greater impairment in functional capacity and a significant increase in mortality in patients with advanced with advanced heart failure[J].J Am Coil Cardio1,2002;39(16):1780-6.
4Silverberg DS,Wexler D,laina A.The role of anemia in the propression of congestive heart failure.Is there a place for erythropoietin and intravenous iron[J].J Nephrol,2004;17(6):749-61.
5Tanner H,Mosehovitis G,Kuster GM,et al.The prevalence of anemia in chronic heart failure[J].Intern J Cardiol,2002;86:115-21.
6Caiola K,Cheng JW.Use of erythropoietin in heart failure management[J].Ann Pharmacother,2004;38:2145-9.
7McClellan WM,Flanders WD,Langston RD,et al.Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals:a population-based study[J].J Am Soc Nephrol,2002;13:1928-6.
2Tanner H, Moschovitis G, Kuster G M, et al. The prevalence of anemia in chronic heart failure[J], Int J Cardiol, 2002, 86(1): 115-121.
3John I A, McMurra Y J V, Whitmore J, et al. Anemia and it's relationship to clinical outcome in heart failure [J]. Circulation, 2004, 10(1): 149-154.
4Horwich T B, Fonarow G C, Hamilton M A, et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced with advanced heart failure[J]. J Am Coll Cardiol. 2002, 39(16): 1780-1786.
5van der Meer,r P, Voors A A, Lipsie E, et al. Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure[J]. J Am CollCardiol, 2004, 44(1): 63-67.
6Silverberg D S, Wexler D, laina A. The role of anemia in the propression of congestive heart failure. Is there a place for erythropoietin and intravenous iron[J]. J Nephrol, 2004, 17(6): 749-761.
5Baruch L,Glazer RD,Aknay N,et al.Morbidity,mortality,physiolngic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial(Val-HeFT)[J].Am Heart J,2004;148:951-7.
6Juurlink DN,Muhammad MM,Lee DS,et al.Rates of hyperkalemia after publication of the Randomized Aldactone Evduation study[J].N Engl J Med,2004;351:543-51.
8Gheorgh iade M,Abraham WT,A lbert NM,et a.l Re lationsh ip between adm issionserum sod ium concentration and clin-ical outcom es in patients hosp italized fo rheart fa ilure:an analy sis from the OPT M IZE-HF reg istry[J].Eur Heart J,2012,28:980-988.
9LicatagD I,PasqualeP,ParrinelloG,et a.l Effects of highdose furosem ide and sm a ll-volume hypertonic saline so lution infus ion in comparision w ith a high dose o f furosem ideas bo lus in refractory congestive heart failure long-termeffects[J].Am H eart J,2012,145(3):459-466.
